Recently published data from four phase 3 safety and efficacy trials show that the synthetic peptide-based, erythropoietin mimetic, peginesatide, is noninferior to conventional erythropoiesis-stimulating agents in increasing haemoglobin levels in patients with chronic kidney disease (CKD). However, peginesatide therapy increased the risk of a combined cardiovascular end point in patients with CKD not on dialysis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
BioDrugs Open Access 13 June 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wrighton, N. C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458–464 (1996).
Fishbane, S. et al. Peginesatide in patients with anemia undergoing hemodialysis. N. Engl. J. Med. 368, 307–319 (2013).
Macdougall, I. C. et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320–332 (2013).
Stead, R. B. et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietin agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108, 1830–1834 (2006).
Macdougall, I. C. et al. Does-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 6, 2579–2586 (2011).
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl. 2, 279–335 (2012).
Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).
Singh, A. K. et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
Pfeffer, M. A. et al. A trial of darbepoetin α in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).
Macdougall, I. C. et al. A peptide-based erythropoietin-receptor agonist for pure red cell aplasia. N. Engl. J. Med. 361, 1848–1855 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K.-U. Eckardt is a consultant for and/or has received speaker's honoraria from Affymax, Amgen, Bayer, GlaxoSmithKline, Johnson & Johnson and Roche.
Rights and permissions
About this article
Cite this article
Eckardt, KU. The safety and efficacy of peginesatide in patients with CKD. Nat Rev Nephrol 9, 192–193 (2013). https://doi.org/10.1038/nrneph.2013.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.42
This article is cited by
-
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
BioDrugs (2022)
-
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Nature Reviews Nephrology (2016)